News | March 30, 2026
Sun Pharma to spotlight 14 dermatology studies at 2026 AAD annual meeting
The presentations underscore the company’s deep expertise in dermatology and immunology
The presentations underscore the company’s deep expertise in dermatology and immunology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
The campaign highlights a straightforward, achievable approach to health, proving that supporting your wellness doesn’t have to be complicated
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
Subscribe To Our Newsletter & Stay Updated
